Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

Saved in:
Bibliographic Details
Published inLeukemia Vol. 29; no. 2; pp. 510 - 514
Main Authors Suzuki, R, Hideshima, T, Mimura, N, Minami, J, Ohguchi, H, Kikuchi, S, Yoshida, Y, Gorgun, G, Cirstea, D, Cottini, F, Jakubikova, J, Tai, Y-T, Chauhan, D, Richardson, P G, Munshi, N C, Utsugi, T, Anderson, K C
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.02.2015
Nature Publishing Group
Subjects
14/63
631/67/1059/602
64/60
82/29
96/31
Animals
Anticancer properties
Antineoplastic Agents - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Antitumor agents
Apoptosis
Benzamides - administration & dosage
Boronic Acids - administration & dosage
Bortezomib
Cancer Research
Cell Line
Cell Line, Tumor
Cell Proliferation
Cell Survival
Critical Care Medicine
Drug Screening Assays, Antitumor
Drug therapy
Genetic aspects
Health aspects
Heat shock proteins
Hematology
HSP90 Heat-Shock Proteins - antagonists & inhibitors
Humans
Intensive
Internal Medicine
letter-to-the-editor
Medicine
Medicine & Public Health
Mice
Mice, SCID
Monomeric GTP-Binding Proteins - metabolism
Multiple myeloma
Multiple Myeloma - drug therapy
Mutation
Neoplasm Transplantation
Oncology
Physiological aspects
Pyrazines - administration & dosage
Pyrazoles - administration & dosage
Retinal Pigment Epithelium - cytology
Australia
United States
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2014.300